• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Morphic Holding Inc. (Amendment)

    2/15/24 11:38:45 AM ET
    $MORF
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MORF alert in real time by email
    SC 13G/A 1 morf13ga4.htm

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934
    (Amendment No. 4)

    Morphic Holding, Inc.
    (Name of Issuer)

     

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

     

    61775R105

    (CUSIP Number)
    December 31, 2023
    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [X] Rule 13d-1(b)
    [X] Rule 13d-1(c)
    [   ] Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

     1 
    CUSIP No. 61775R105

     

     

      1. Names of Reporting Persons.
        EcoR1 Capital, LLC
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) X  
        (b)    
             
      3. SEC Use Only  
         
      4. Citizenship or Place of Organization Delaware
               

     

    Number of
    Shares
    Beneficially
    Owned by
    Each Reporting
    Person With:
    5. Sole Voting Power -0-  
    6. Shared Voting Power 211,262  
    7. Sole Dispositive Power -0-  
    8. Shared Dispositive Power 211,262  

     

      9. Aggregate Amount Beneficially Owned by Each Reporting Person 211,262
      10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
    ________
      11. Percent of Class Represented by Amount in Row (9) 0.4%
      12. Type of Reporting Person (See Instructions) OO, IA

     

     

     2 
    CUSIP No. 61775R105

     

     

      1. Names of Reporting Persons.
        Oleg Nodelman
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) X  
        (b)    
             
      3. SEC Use Only  
         
      4. Citizenship or Place of Organization United States
               

     

    Number of
    Shares
    Beneficially
    Owned by
    Each Reporting
    Person With:
    5. Sole Voting Power -0-  
    6. Shared Voting Power 211,262  
    7. Sole Dispositive Power -0-  
    8. Shared Dispositive Power 211,262  

     

      9. Aggregate Amount Beneficially Owned by Each Reporting Person 211,262
      10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
    ________
      11. Percent of Class Represented by Amount in Row (9) 0.4%
      12. Type of Reporting Person (See Instructions) IN, HC

     

     

     3 
    CUSIP No. 61775R105

     

     

      1. Names of Reporting Persons.
        EcoR1 Capital Fund Qualified, L.P.
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a)    
        (b)    
             
      3. SEC Use Only  
         
      4. Citizenship or Place of Organization Delaware
               

     

    Number of
    Shares
    Beneficially
    Owned by
    Each Reporting
    Person With:
    5. Sole Voting Power -0-  
    6. Shared Voting Power 199,756  
    7. Sole Dispositive Power -0-  
    8. Shared Dispositive Power 199,756  

     

      9. Aggregate Amount Beneficially Owned by Each Reporting Person 199,756
      10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
    ________
      11. Percent of Class Represented by Amount in Row (9) 0.4%
      12. Type of Reporting Person (See Instructions) PN

     

     

     4 
    CUSIP No. 61775R105

     

     

    Item 1.    
      (a) Name of Issuer
        Morphic Holding, Inc.
      (b) Address of Issuer’s Principal Executive Offices
        35 Gatehouse Drive, A2, Waltham, MA 02451
         
    Item 2.    
      (a) The names of the persons filing this statement are:
        EcoR1 Capital Fund Qualified, L.P. (“Qualified Fund”); EcoR1 Capital, LLC (“EcoR1”) and Oleg Nodelman (“Nodelman”) (collectively, the “Filers”).
        Qualified Fund is filing this statement jointly with the other Filers, but not as a member of a group and it expressly disclaims membership in a group.  In addition, filing this Schedule 13G on behalf of Qualified Fund should not be construed as an admission that it is, and it disclaims that it is, a beneficial owner, as defined in Rule 13d-3 under the Act, of any of the Stock covered by this Schedule 13G.
        Each Filer also disclaims beneficial ownership of the Stock except to the extent of that person’s pecuniary interest therein.  
      (b) The principal business office of the Filers is located at:
        357 Tehama Street #3, San Francisco, CA  94103
      (c) For citizenship of Filers, see Item 4 of the cover sheet for each Filer.
      (d) This statement relates to the Issuer’s shares of Common Stock, par value $0.0001 per share (the “Stock”).
      (e) The CUSIP number of the Issuer is:  61775R105.

     

     5 
    CUSIP No. 61775R105

     

     

    Item 3. If this statement is filed pursuant to rule 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
      (a) [    ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
      (b) [    ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
      (c) [    ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
      (d) [    ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
      (e) [ X ] An investment adviser in accordance with section 240.13d-1(b)(1)(ii)(E) as to EcoR1.
      (f) [    ] An employee benefit plan or endowment fund in accordance with section 240.13d-1(b)(1)(ii)(F).
      (g) [ X ] A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G) as to Mr. Nodelman.
      (h) [    ] A savings association as defined in section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).
      (i) [    ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).
      (j) [    ] Group, in accordance with section 240.13d-1(b)(1)(ii)(J).
    Item 4. Ownership.
     

    See Items 5-9 and 11 of the cover page for each Filer.

    The percentages reported in this Schedule 13G are based on 49,742,966 shares of Common Stock outstanding as of October 31, 2023, as reported in the Issuer’s Form 10-Q filed on November 3, 2023.

    Item 5. Ownership of Five Percent or Less of a Class
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following    [ X ].
    Item 6. Ownership of More than Five Percent on Behalf of Another Person.
      The funds managed by EcoR1, including Qualified Fund, hold the Stock for the benefit of their investors and have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Stock.
     6 
    CUSIP No. 61775R105

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.
      Not applicable.
    Item 8. Identification and Classification of Members of the Group.
      EcoR1 is the general partner and investment adviser of investment funds, including Qualified Fund.  Mr. Nodelman is the control person of EcoR1.
    Item 9. Notice of Dissolution of Group.
      Not applicable.
    Item 10. Certification.
       
    Certification of EcoR1 and Mr. Nodelman:
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
    Certification of Qualified Fund:
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     7 
    CUSIP No. 61775R105

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: February 14, 2024

     

    EcoR1 CAPITAL, LLC    

     

     

    By:

     

     

    /s/ Oleg Nodelman

     

     

     

    /s/ Oleg Nodelman

      Oleg Nodelman, Manager   Oleg Nodelman
           
           
    EcoR1 CAPITAL FUND QUALIFIED, L.P.    

     

    By:

     

    EcoR1 Capital, LLC, General Partner

       
     

     

     

       
      By: /s/ Oleg Nodelman    
        Oleg Nodelman, Manager    

     

     

     8 
    CUSIP No. 61775R105

    EXHIBIT A

    AGREEMENT REGARDING JOINT FILING
    OF STATEMENT ON SCHEDULE 13D OR 13G

    The undersigned agree to file jointly with the Securities and Exchange Commission (the “SEC”) any and all statements on Schedule 13D, Schedule 13G or Forms 3, 4 or 5 (and any amendments or supplements thereto) required under section 13(d) or 16(a) of the Securities Exchange Act of 1934, as amended, in connection with purchases by the undersigned of the securities of any issuer. For that purpose, the undersigned hereby constitute and appoint EcoR1 Capital, LLC a Delaware limited liability company, as their true and lawful agent and attorney-in-fact, with full power and authority for and on behalf of the undersigned to prepare or cause to be prepared, sign, file with the SEC and furnish to any other person all certificates, instruments, agreements and documents necessary to comply with section 13(d) and section 16(a) of the Securities Exchange Act of 1934, as amended, in connection with said purchases, and to do and perform every act necessary and proper to be done incident to the exercise of the foregoing power, as fully as the undersigned might or could do if personally present.

    Dated: February 14, 2024

    EcoR1 CAPITAL, LLC    

     

     

    By:

     

     

    /s/ Oleg Nodelman

     

     

     

    /s/ Oleg Nodelman

      Oleg Nodelman, Manager   Oleg Nodelman
           
           
    EcoR1 CAPITAL FUND QUALIFIED, L.P.    

     

    By:

     

    EcoR1 Capital, LLC, General Partner

       
     

     

     

       
      By: /s/ Oleg Nodelman    
        Oleg Nodelman, Manager    

     

     

    Get the next $MORF alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $MORF

    DatePrice TargetRatingAnalyst
    12/8/2023$46.00Buy
    Citigroup
    9/25/2023$61.00 → $33.00Hold
    Stifel
    9/25/2023Buy → Neutral
    BTIG Research
    8/9/2023$69.00 → $61.00Buy → Hold
    Stifel
    9/7/2022$44.00Buy
    Stifel
    7/20/2022$45.00Outperform
    SVB Leerink
    3/31/2022$68.00Buy
    Canaccord Genuity
    2/25/2022$82.00 → $76.00Outperform
    RBC Capital
    More analyst ratings

    $MORF
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Edwards Martin bought $48,803 worth of shares (2,376 units at $20.54) (SEC Form 4)

      4 - Morphic Holding, Inc. (0001679363) (Issuer)

      11/15/23 7:00:10 PM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Slattery Joseph P bought $49,436 worth of shares (2,400 units at $20.60), increasing direct ownership by 36% to 9,066 units (SEC Form 4)

      4 - Morphic Holding, Inc. (0001679363) (Issuer)

      11/14/23 7:04:11 PM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MORF
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Omega Funds Closes Oversubscribed $647 Million Fund VIII to Invest in Transformative Life Science Companies

      Omega Funds, a leading international healthcare venture capital firm focused on delivering impactful medicines to patients, today announced the closing of its eighth fund with $647 million in capital commitments. The new fund, Omega Fund VIII, L.P. ("Fund VIII"), was oversubscribed, exceeding its target of $600 million, garnering strong support from both new and existing limited partners. With Fund VIII, the firm will continue to execute its strategy of creating and investing in innovative life sciences companies in the U.S. and Europe that target severe, unmet medical needs. Since its inception in 2004, Omega Funds has raised $2.5 billion to invest in exceptional entrepreneurs developing

      7/21/25 7:00:00 AM ET
      $BBNX
      $BCAX
      $KMTS
      $MORF
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Lilly Completes Acquisition of Morphic to Improve Outcomes and Expand Options for People Living with Inflammatory Bowel Disease

      Broadens Lilly's immunology pipeline with Morphic's oral integrin therapies, including MORF-057 Reinforces the company's strategy of delivering potential first or best-in-class therapies in the field of gastroenterology INDIANAPOLIS, Aug. 16, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the successful completion of its acquisition of Morphic Holding, Inc. (NASDAQ:MORF). Morphic is a biopharmaceutical company developing oral integrin therapies for treatment of serious chronic diseases, including a selective oral small molecule inhibitor of α4β7 integrin (known as MORF-057) for inflammatory bowel disease (IBD). "We are committed to exploring innovative approaches for i

      8/16/24 8:38:00 AM ET
      $LLY
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lilly to Acquire Morphic to Improve Outcomes for Patients with Inflammatory Bowel Disease

      Acquisition to expand Lilly's immunology pipeline with oral integrin therapies INDIANAPOLIS and WALTHAM, Mass., July 8, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and Morphic Holding, Inc. (NASDAQ:MORF) today announced a definitive agreement for Lilly to acquire Morphic, a biopharmaceutical company developing oral integrin therapies for treatment of serious chronic diseases. Morphic's lead program is a selective oral small molecule inhibitor of α4β7 integrin for the treatment of inflammatory bowel disease (IBD) that has the potential to improve outcomes and expand treatment options for patients. This molecule (known as MORF-057) is being evaluated in two Phase 2 studies in ulcera

      7/8/24 6:45:00 AM ET
      $LLY
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MORF
    Financials

    Live finance-specific insights

    See more
    • Lilly Completes Acquisition of Morphic to Improve Outcomes and Expand Options for People Living with Inflammatory Bowel Disease

      Broadens Lilly's immunology pipeline with Morphic's oral integrin therapies, including MORF-057 Reinforces the company's strategy of delivering potential first or best-in-class therapies in the field of gastroenterology INDIANAPOLIS, Aug. 16, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the successful completion of its acquisition of Morphic Holding, Inc. (NASDAQ:MORF). Morphic is a biopharmaceutical company developing oral integrin therapies for treatment of serious chronic diseases, including a selective oral small molecule inhibitor of α4β7 integrin (known as MORF-057) for inflammatory bowel disease (IBD). "We are committed to exploring innovative approaches for i

      8/16/24 8:38:00 AM ET
      $LLY
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Morphic Announces Corporate Highlights and Financial Results for the Third Quarter 2023

      -Presented positive EMERALD-1 Phase 2a data for MORF-057 in patients with moderate to severe ulcerative colitis at UEG Week 2023- -Continued enrollment on target in EMERALD-2 Phase 2b trial of MORF-057 in ulcerative colitis- -Ended third quarter with $725.1 million in cash, cash equivalents, and marketable securities providing runway into the second half of 2027- WALTHAM, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ:MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today reported corporate highlights and financial results for the third quarter 2023. "Morphic presented a compre

      11/3/23 7:00:00 AM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Morphic Therapeutic to Host Webcast to Present EMERALD-1 Full Data Set

      WALTHAM, Mass., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ:MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced it will host a webcast and conference call to discuss the complete results from the open-label EMERALD-1 Phase 2a study of MORF-057 in adults with moderate to severe ulcerative colitis. The positive topline results from EMERALD-1 were reported in April of this year and the full data set will be presented at the upcoming UEG Week 2023. The webcast and call will be held at 7:45 AM Eastern Time on October 12, 2023. A live webcast of the call will be available via

      10/9/23 8:00:00 AM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MORF
    Leadership Updates

    Live Leadership Updates

    See more
    • Morphic Appoints Dr. Simon Cooper as Chief Medical Officer

      WALTHAM, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ:MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Simon Cooper, M.B.B.S., has joined the Company as Chief Medical Officer. Dr. Cooper is an accomplished leader in drug development with appreciable success and a proven history across all phases of clinical development and in a wide variety of therapeutic areas, particularly autoimmune, inflammatory, cardiovascular, and pulmonary diseases. Dr. Cooper most recently served as Chief Medical Officer of Keros Therapeutics. "Simon brings clinical development expe

      3/19/24 8:00:00 AM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Morphic Announces Corporate Highlights and Financial Results for the Full Year 2022

      -Initiated and completed enrollment for EMERALD-1 phase 2a trial of MORF-057 in ulcerative colitis; topline data expected 2Q23- -Launched EMERALD-2 phase 2b global randomized trial of MORF-057 in ulcerative colitis- -Ended 2022 with $348 million in cash and equivalents; ~$100 million from February private placement extends cash runway into second half of 2026 WALTHAM, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ:MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today reported corporate highlights and financial results for the full year 2022. 2022 and Recent Corporate H

      2/23/23 8:00:00 AM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Morphic Appoints Joanne Gibbons as Senior Vice President of Regulatory Affairs

      WALTHAM, Mass., May 18, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ:MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Joanne Gibbons has been named Senior Vice President of Regulatory Affairs. Ms. Gibbons was previously Vice President and Head of Regulatory Affairs at Codiak Biosciences. "Joanne arrives at Morphic at a promising time. We are advancing clinical and pre-clinical integrin inhibitors generated by the MInT Platform and Joanne brings successful leadership experience across the full spectrum of regulatory affairs from preclinical activities through drug commer

      5/18/22 7:30:00 AM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MORF
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Edwards Martin returned 2,376 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Morphic Holding, Inc. (0001679363) (Issuer)

      8/21/24 4:36:17 PM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Slattery Joseph P returned 9,066 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Morphic Holding, Inc. (0001679363) (Issuer)

      8/20/24 7:12:13 PM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Nashat Amir closing all direct ownership in the company (SEC Form 4)

      4 - Morphic Holding, Inc. (0001679363) (Issuer)

      8/20/24 7:11:28 PM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MORF
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Citigroup initiated coverage on Morphic with a new price target

      Citigroup initiated coverage of Morphic with a rating of Buy and set a new price target of $46.00

      12/8/23 7:51:26 AM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stifel reiterated coverage on Morphic with a new price target

      Stifel reiterated coverage of Morphic with a rating of Hold and set a new price target of $33.00 from $61.00 previously

      9/25/23 11:48:40 AM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Morphic downgraded by BTIG Research

      BTIG Research downgraded Morphic from Buy to Neutral

      9/25/23 7:17:39 AM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MORF
    SEC Filings

    See more
    • SEC Form 15-12G filed by Morphic Holding Inc.

      15-12G - Morphic Holding, Inc. (0001679363) (Filer)

      8/26/24 7:39:57 AM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Morphic Holding Inc.

      S-8 POS - Morphic Holding, Inc. (0001679363) (Filer)

      8/16/24 4:27:56 PM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Morphic Holding Inc.

      S-8 POS - Morphic Holding, Inc. (0001679363) (Filer)

      8/16/24 4:25:26 PM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MORF
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Morphic Holding Inc.

      SC 13G/A - Morphic Holding, Inc. (0001679363) (Subject)

      8/12/24 9:40:06 AM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Morphic Holding Inc.

      SC 13G/A - Morphic Holding, Inc. (0001679363) (Subject)

      8/7/24 7:47:40 AM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Morphic Holding Inc.

      SC 13G/A - Morphic Holding, Inc. (0001679363) (Subject)

      7/8/24 10:07:20 AM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care